

## Pharmacy Medical Necessity Guidelines: Acromegaly Agents

Effective: July 1, 2020

Prior Authorization Required	√	Type of Review – Care Management	
Not Covered		Type of Review – Clinical Review	√
Pharmacy (RX) or Medical (MED) Benefit	RX/ MED	Department to Review	RXUM /MM
<p>These pharmacy medical necessity guidelines apply to the following:</p> <p><b>Commercial Products</b></p> <input type="checkbox"/> Tufts Health Plan Commercial products – large group plans <input type="checkbox"/> Tufts Health Plan Commercial products – small group and individual plans <input type="checkbox"/> Tufts Health Freedom Plan products – large group plans <input type="checkbox"/> Tufts Health Freedom Plan products – small group plans <ul style="list-style-type: none"> <li>CareLink<sup>SM</sup> – Refer to CareLink Procedures, Services and Items Requiring Prior Authorization</li> </ul> <p><b>Tufts Health Public Plans Products</b></p> <input type="checkbox"/> Tufts Health Direct – A Massachusetts Qualified Health Plan (QHP) (a commercial product) <input checked="" type="checkbox"/> Tufts Health Together – MassHealth MCO Plan and Accountable Care Partnership Plans <input checked="" type="checkbox"/> Tufts Health RITogether – A Rhode Island Medicaid Plan		<p><b>Fax Numbers:</b></p> <p>RXUM: 617.673.0988 - <i>Somavert</i></p> <p>MM: 888.415.9055 - <i>octreotide, Sandostatin LAR, Signifor LAR</i></p>	

**Note:** This guideline does not apply to Medicare Members (includes dual eligible Members).

### OVERVIEW

#### **FOOD AND DRUG ADMINISTRATION-APPROVED INDICATIONS**

Octreotide is a somatostatin analog indicated for:

- **Acromegaly**  
To reduce blood levels of growth hormone (GH) and insulin like growth factor (IGF-I) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses
- **Carcinoid Tumors**  
For the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease
- **Vasoactive Intestinal Peptide Tumors**  
For the treatment of the profuse watery diarrhea associated with Vasoactive Intestinal Peptide-secreting tumors

Sandostatin LAR (octreotide) is a somatostatin analog indicated for:

- **Acromegaly**  
Long-term maintenance therapy in acromegalic patients who have had an inadequate response to surgery and/or radiotherapy or for whom surgery and/or radiotherapy is not an option. The goal of treatment in acromegaly is to reduce growth hormone and IGF-1 levels to normal
- **Carcinoid Tumors**  
Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors
- **VIPomas**  
Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors

Signifor LAR (pasireotide) is a somatostatin analog indicated for the treatment of:

- **Acromegaly**  
Patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option
- **Cushing's disease**  
Cushing's disease for whom pituitary surgery is not an option or has not been curative

Somavert (pegvisomant) is a growth hormone receptor antagonist indicated for the treatment of:

- **Acromegaly**

Acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate

### **COVERAGE GUIDELINES**

The plan may authorize coverage of **octreotide or Sandostatin LAR (octreotide)** for Members when all of the following criteria are met:

#### **Carcinoid tumors, Vasoactive Intestinal Peptide Tumors**

1. Documented diagnosis of one of the following:
  - a. Carcinoid tumor
  - b. Vasoactive intestinal peptide tumor

The plan may authorization coverage of **octreotide, Sandostatin LAR (octreotide), Signifor LAR (pasireotide), or Somavert (pegvisomant)** for Members when all of the following criteria are met:

#### **Acromegaly**

##### Initial Therapy

1. Documented diagnosis of acromegaly
- AND**
2. The prescribing physician is an endocrinologist
- AND**
3. Documentation the Member is not a candidate for surgery and/or radiation, or has had an inadequate response to surgery and/or radiation

In addition to the above criteria, the plan may authorize coverage of Sandostatin LAR (octreotide), Signifor LAR (pasireotide), or Somavert (pegvisomant) for Members when all of the following criteria are met:

1. Documentation the Member has had a failure of, or is unable to tolerate, a treatment regimen that included octreotide or Somatuline Depot (lanreotide)

##### Reauthorization Criteria

1. Documented diagnosis of acromegaly
- AND**
2. The prescribing physician is an endocrinologist
- AND**
3. Documentation of a reduction in baseline growth hormone and/or insulin-like growth factor serum concentrations

In addition to the above criteria, the plan may authorize coverage of Sandostatin LAR (octreotide), Signifor LAR (pasireotide), or Somavert (pegvisomant) for Members when all of the following criteria are met:

1. Documentation the Member has had a failure of, or is unable to tolerate, a treatment regimen that included octreotide or Somatuline Depot (lanreotide)

The plan may authorize coverage of **Signifor LAR** for Members when all of the following criteria are met:

#### **Cushing's disease**

##### Initial Therapy

1. Documented diagnosis of Cushing's disease
- AND**
2. Documentation that pituitary surgery is not an option or has not been curative for the Member
- AND**
3. The prescribing physician is an endocrinologist
- AND**
4. Member is 18 years of age or older

##### Reauthorization Criteria

1. Documented diagnosis of Cushing's disease
- AND**
2. The prescribing physician is an endocrinologist
- AND**
3. Member is at least 18 years of age
- AND**
4. Documentation of a reduction in baseline 24-hour urinary free cortisol levels

## LIMITATIONS

- The coverage of Sandostatin (octreotide) immediate-release is limited to 90 single dose vials or 30 multidose vials per 28 days.
- The coverage of Sandostatin LAR (octreotide) is limited to 1 kit per 28 days.
- The coverage of Somatuline Depot (lanreotide) is limited to 1 kit per 28 days.
- The coverage of Somavert (pegvisomant) is limited to a maximum daily dose of two; up to 32 single dose vials for the first 28 days then up to 56 single dose vials per 28 days.
- For Signifor LAR for the treatment of Cushing's disease, initial approval will be limited to 3 months. Reauthorization of Signifor LAR (pasireotide) will be provided in 12-month intervals.
- For acromegaly, initial approval will be limited to 6 months. Reauthorization of the requested medication will be provided in 12-month intervals.
- Members new to the plan stable on the requested medication should be reviewed against Reauthorization Criteria when the requested use is acromegaly or Cushing's disorder.

## CODES

The following HCPCS/CPT code(s) are:

Code	Description
J1930	Injection, lanreotide, 1 mg
J2353	Injection, octreotide, depot form for intramuscular injection, 1 mg
J2354	Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg
J2502	Injection, pasireotide long acting, 1 mg

## REFERENCES

1. Bernabeu I, Alvarez-Escolá C, Paniagua AE et al. Pegvisomant and cabergoline combination therapy in acromegaly. *Pituitary*. 2012 Mar 7.
2. Broder MS, Neary MP, Chang E, et al. Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases. *Pituitary*. 2014 Aug;17(4):333-41.
3. Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. *J Clin Endocrinol Metab*. 2014 Mar;99(3):791-9.
4. Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. *Lancet Diabetes Endocrinol*. 2014 Nov;2(11):875-84.
5. Katznelson L, Atkinson JL, Cook DM et al. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update. *Endocr Pract*. 2011 Jul-Aug; 17 Suppl 4:1-44.
6. Mathioudakis N, Salvatori R. Management options for persistent postoperative acromegaly. *Neurosurg Clin N Am*. 2012 Oct; 23(4):621-38.
7. Melmed S, Casanueva FF, Cavagnini F, et al. Guidelines for acromegaly management. *J Clin Endocrinol Metab*. 2002; 87:4054-4058.
8. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. *J Clin Endocrinol Metab*. 2009; 94:1509-1517.
9. Plöckinger U. Medical therapy of acromegaly. *Int J Endocrinol*. 2012; 2012:268957.
10. Sandostatin (octreotide acetate) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2012.
11. Sandostatin LAR (octreotide acetate for injectable suspension) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2016.
12. Sheppard M, Bronstein MD, Freda P, et al. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. *Pituitary*. 2015 Jun;18(3):385-94.
13. Shlomo, M. Acromegaly. *N Engl J Med*. December 14, 2006; Vol. 355 (24): 2558-2573.
14. Signifor LAR (pasireotide) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2018.
15. Somavert (pegvisomant for injection) [prescribing information]. New York, NY: Pharmacia & Upjohn Co; January 2016.
16. The National Endocrine and Metabolic Diseases Information Service. NIH Publication No. 07-3924, April 2007: [endocrine.niddk.nih.gov/pubs/acro/acro.htm](http://endocrine.niddk.nih.gov/pubs/acro/acro.htm).

17. Trainer PJ, Drake WM, Katznelson L, et.al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. *N Engl J Med* 2000; 342:1171-1177.
18. van der Lely AJ, Biller BM, Brue T et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. *J Clin Endocrinol Metab.* 2012 May; 97(5):1589-97.

#### **APPROVAL HISTORY**

April 14, 2015: Reviewed by Pharmacy & Therapeutics Committee.

Subsequent endorsement date(s) and changes made:

1. May 12, 2015: Added Signifor LAR (pasireotide) to Medical Necessity Guidelines.
2. June 9, 2015: Administrative update: added HCPCS code C9454 to policy.
3. January 1, 2016: Administrative change to rebranded template.
4. May 10, 2016: Administrative update: Replaced C9454 with J2502.
5. February 14, 2017: Removed somatuline depot from the Medical Necessity Guideline.
6. April 11, 2017: Administrative update, Adding Tufts Health RITogether to the template
7. February 13, 2018: Effective February 19, 2018, Medical Necessity Guideline applies to Tufts Health RITogether. Administrative update: Removed Limitation #5 (Signifor LAR [pasireotide] is covered under the medical benefit only) to be in line with current coverage.
8. February 12, 2019: For Acromegaly, updated the criteria to "Documentation the Member has a diagnosis of acromegaly from an endocrinologist." Added coverage criteria for Signifor LAR for new supplemental indication for Cushing's disease.
9. April 14, 2020: Effective July 1, 2020, modified reauthorization criteria for acromegaly and Cushing's disease and added the following Limitation: "Members new to the plan stable on the requested medication should be reviewed against Reauthorization Criteria when the requested use is acromegaly or Cushing's disorder." Updated coverage criteria to require a documented diagnosis of Cushing's disease. Aligned coverage criteria with FDA-approved indications for medications included in the Medical Necessity Guideline and removed any off-label indications from coverage criteria.

#### **BACKGROUND, PRODUCT AND DISCLAIMER INFORMATION**

Pharmacy Medical Necessity Guidelines have been developed for determining coverage for plan benefits and are published to provide a better understanding of the basis upon which coverage decisions are made. The plan makes coverage decisions on a case-by-case basis considering the individual member's health care needs. Pharmacy Medical Necessity Guidelines are developed for selected therapeutic classes or drugs found to be safe, but proven to be effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in the service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations. The plan revises and updates Pharmacy Medical Necessity Guidelines annually, or more frequently if new evidence becomes available that suggests needed revisions.

For self-insured plans, coverage may vary depending on the terms of the benefit document. If a discrepancy exists between a Pharmacy Medical Necessity Guideline and a self-insured Member's benefit document, the provisions of the benefit document will govern.

Treating providers are solely responsible for the medical advice and treatment of members. The use of this policy is not a guarantee of payment or a final prediction of how specific claim(s) will be adjudicated. Claims payment is subject to member eligibility and benefits on the date of service, coordination of benefits, referral/authorization and utilization management guidelines when applicable, and adherence to plan policies and procedures and claims editing logic.

[Provider Services](#)